• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.

作者信息

Boissard F, Fournié J-J, Quillet-Mary A, Ysebaert L, Poupot M

机构信息

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Université Toulouse III Paul-Sabatier, ERL 5294 CNRS, Toulouse, France.

Laboratoire d'Excellence 'TOUCAN', Programme Hospitalo-Universitaire en Cancérologie CAPTOR, Institut Carnot Lymphome CALYM, Pierre-Benite, France.

出版信息

Blood Cancer J. 2015 Oct 2;5(10):e355. doi: 10.1038/bcj.2015.74.

DOI:10.1038/bcj.2015.74
PMID:26430726
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4635187/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0b/4635187/70cf12d4d1b0/bcj201574f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0b/4635187/60318d3d8aa0/bcj201574f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0b/4635187/70cf12d4d1b0/bcj201574f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0b/4635187/60318d3d8aa0/bcj201574f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd0b/4635187/70cf12d4d1b0/bcj201574f2.jpg

相似文献

1
Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients.类护士细胞介导慢性淋巴细胞白血病患者对依鲁替尼的耐药性。
Blood Cancer J. 2015 Oct 2;5(10):e355. doi: 10.1038/bcj.2015.74.
2
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.依鲁替尼对体内慢性淋巴细胞白血病肿瘤微环境相互作用的破坏——一项研究者发起的II期研究结果
Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9.
3
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.依鲁替尼可改变慢性淋巴细胞白血病中单核细胞/巨噬细胞群体的功能。
Oncotarget. 2016 Oct 4;7(40):65968-65981. doi: 10.18632/oncotarget.11782.
4
Update on ibrutinib.依鲁替尼最新进展
Clin Adv Hematol Oncol. 2013 Nov;11(11):735-7.
5
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.泽布替尼对慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者免疫细胞的影响。
Hematol Oncol. 2019 Oct;37(4):392-400. doi: 10.1002/hon.2667. Epub 2019 Sep 13.
6
Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.依鲁替尼和idelalisib可阻断与慢性淋巴细胞白血病（CLL）细胞在肿瘤微环境中的黏附和激活相关的免疫表型变化。
Leuk Lymphoma. 2018 Aug;59(8):1927-1937. doi: 10.1080/10428194.2017.1403598. Epub 2017 Nov 22.
7
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.NOTCH1 活性降低与慢性淋巴细胞白血病对依鲁替尼的反应相关。
Clin Cancer Res. 2019 Dec 15;25(24):7540-7553. doi: 10.1158/1078-0432.CCR-19-1009. Epub 2019 Oct 2.
8
CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.CD69表达可能预测对苯达莫司汀的反应，而依鲁替尼或idelalisib对其的调节可增强慢性淋巴细胞白血病中的细胞毒性作用。
Oncotarget. 2016 Feb 2;7(5):5507-20. doi: 10.18632/oncotarget.6685.
9
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.B细胞受体抑制剂在慢性淋巴细胞白血病患者治疗中的作用。
Haematologica. 2015 Dec;100(12):1495-507. doi: 10.3324/haematol.2014.119123.
10
Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.解析慢性淋巴细胞白血病中依鲁替尼耐药性
J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14.

引用本文的文献

1
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.慢性淋巴细胞白血病中靶向治疗的耐药性：临床与诊断实践的现状及展望
Leukemia. 2025 Jun 24. doi: 10.1038/s41375-025-02662-y.
2
Interactions with and activation of immune cells by CD41a extracellular vesicles.CD41a细胞外囊泡与免疫细胞的相互作用及激活
Front Immunol. 2025 Feb 14;16:1509078. doi: 10.3389/fimmu.2025.1509078. eCollection 2025.
3
NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy.

本文引用的文献

1
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.依鲁替尼抑制BCR和NF-κB信号传导，并减少慢性淋巴细胞白血病患者组织驻留细胞中的肿瘤增殖。
Blood. 2014 May 22;123(21):3286-95. doi: 10.1182/blood-2014-02-548610. Epub 2014 Mar 21.
2
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.BTK 抑制可通过其对 B 细胞受体信号活性的影响来靶向体内 CLL 增殖。
Leukemia. 2014 Mar;28(3):649-57. doi: 10.1038/leu.2013.358. Epub 2013 Nov 25.
3
Ibrutinib in relapsed chronic lymphocytic leukemia.
NOD2 激活增强了巨噬细胞 Fcγ 受体功能，并可能提高抗体治疗的效果。
Front Immunol. 2024 Jun 11;15:1409333. doi: 10.3389/fimmu.2024.1409333. eCollection 2024.
4
Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing.慢性淋巴细胞白血病和 Richter 转化的小鼠模型：我们学到了什么，以及我们还缺少什么。
Front Immunol. 2024 Jun 6;15:1376660. doi: 10.3389/fimmu.2024.1376660. eCollection 2024.
5
Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia.活性己糖相关化合物对慢性淋巴细胞白血病具有直接和间接作用。
Nutrients. 2023 Dec 18;15(24):5138. doi: 10.3390/nu15245138.
6
Unraveling the Bone Tissue Microenvironment in Chronic Lymphocytic Leukemia.解析慢性淋巴细胞白血病中的骨组织微环境
Cancers (Basel). 2023 Oct 19;15(20):5058. doi: 10.3390/cancers15205058.
7
Macrophage-Based Therapeutic Strategies in Hematologic Malignancies.血液系统恶性肿瘤中基于巨噬细胞的治疗策略
Cancers (Basel). 2023 Jul 22;15(14):3722. doi: 10.3390/cancers15143722.
8
An agent-based model of monocyte differentiation into tumour-associated macrophages in chronic lymphocytic leukemia.慢性淋巴细胞白血病中单核细胞分化为肿瘤相关巨噬细胞的基于主体的模型。
iScience. 2023 May 19;26(6):106897. doi: 10.1016/j.isci.2023.106897. eCollection 2023 Jun 16.
9
Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL.增强共刺激信号可改善 CLL 中 CAR T 细胞的效应器反应。
Cancer Res Commun. 2022 Sep 30;2(9):1089-1103. doi: 10.1158/2767-9764.CRC-22-0200. eCollection 2022 Sep.
10
Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21.成纤维样细胞通过 CCL21 的替代产生将 B 细胞隔离在慢性淋巴细胞白血病中紊乱的淋巴结内。
Blood Adv. 2022 Aug 23;6(16):4691-4704. doi: 10.1182/bloodadvances.2021006169.
伊布替尼用于复发的慢性淋巴细胞白血病
N Engl J Med. 2013 Sep 26;369(13):1278-9. doi: 10.1056/NEJMc1309710.
4
B cell receptor signaling in chronic lymphocytic leukemia.B 细胞受体信号转导在慢性淋巴细胞白血病中的作用。
Trends Immunol. 2013 Dec;34(12):592-601. doi: 10.1016/j.it.2013.07.002. Epub 2013 Aug 5.
5
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.伊布替尼治疗复发慢性淋巴细胞白血病的 BTK 靶点。
N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.
6
Genomic and phenotypic characterization of nurse-like cells that promote drug resistance in chronic lymphocytic leukemia.促进慢性淋巴细胞白血病耐药的类淋巴母细胞的基因组和表型特征。
Leuk Lymphoma. 2011 Jul;52(7):1404-6. doi: 10.3109/10428194.2011.568078.
7
An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease.肝细胞生长因子与其受体（c-MET）之间的相互作用通过 STAT3 磷酸化延长慢性淋巴细胞白血病细胞的存活：间充质细胞在疾病中的潜在作用。
Haematologica. 2011 Jul;96(7):1015-23. doi: 10.3324/haematol.2010.029736. Epub 2011 Apr 12.
8
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.布鲁顿酪氨酸激酶选择性不可逆抑制剂的发现。
ChemMedChem. 2007 Jan;2(1):58-61. doi: 10.1002/cmdc.200600221.
9
Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia.在慢性淋巴细胞白血病背景下分化的“护士样”细胞的独特特征。
Blood. 2002 Feb 1;99(3):1030-7. doi: 10.1182/blood.v99.3.1030.
10
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.血液来源的类成纤维细胞通过基质细胞衍生因子-1保护慢性淋巴细胞白血病B细胞免于自发凋亡。
Blood. 2000 Oct 15;96(8):2655-63.